Researchers at the University of Sydney have made a groundbreaking discovery that could potentially lower the risk of heart attack and stroke for people with type 2 diabetes. The study found that a protein called SEC61B is significantly increased in the platelets of people with type 2 diabetes, making them more prone to forming blood clots.
The Role of SEC61B in Blood Clotting
The researchers discovered that SEC61B disrupts calcium balance inside platelets, leading to increased platelet activity and clotting. By blocking SEC61B activity with an antibiotic called anisomycin, the researchers were able to reduce platelet clumping in human samples and animal models.
Potential Treatment Opportunities
This discovery opens up new opportunities for treatment and could potentially lead to the development of new therapies to reduce the risk of cardiovascular disease in people with type 2 diabetes. The researchers believe that pre-clinical trials in animals could begin within 1-2 years, with potential therapies for patients on the horizon in the next decade.
Impact on Type 2 Diabetes Management
This breakthrough could have a significant impact on the management of type 2 diabetes, particularly for individuals who are at high risk of cardiovascular disease. By targeting SEC61B, researchers may be able to develop new treatments that can help reduce the risk of heart attack and stroke in people with type 2 diabetes.